Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: A molecular imaging study

Translational Oncology

Volumn 3, Issue 1, 2010, Pages 56-64

  Blankenberg, Francis G ^a   Levashova, Zoia ^a   Sarkar, Susanta K ^b   Pizzonia, John ^c   Backer, Marina V ^d   Backer, Joseph M ^d  

^a STANFORD UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Applications FUJIFILM Medical Systems USA Inc   (United States)

^d SIBTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; TECHNETIUM 99M; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRAFT; CELL COUNT; CONTROLLED STUDY; DRUG MONITORING; DRUG RESPONSE; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PATIENT IDENTIFICATION; PATIENT MONITORING; PROTEIN EXPRESSION; RECEPTOR BINDING; TUMOR; TUMOR VASCULARIZATION; XENOGRAFT;

EID: 71549138874     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09271     Document Type: Article

References (43)

1. Jubb AM, Oates AJ, Holden S, and Koeppen H (2006). Predicting benefit from antiangiogenic agents in malignancy. Nat Rev Cancer 6, 626-635.
2. Hayden EC (2009). Cutting off cancer's supply lines. Nature 458, 686-687.
3. Lin MI and Sessa WC (2004). Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell 6, 529-531.
4. Jain RK, Duda DG, Clark JW, and Loeffler JS (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 1, 24-40.
5. Sessa C, Guiba A, Del Conte G, and Ruegg C (2008). Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 5, 78-91.
6. Ellis LM and Hicklin DJ (2008). VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 8, 579-591.
7. Bergers G and Hanahan D (2008). Modes of resistance to antiangiogenic therapy. Nat Rev Cancer 8, 592-603.
8. Franco M, Man S, Chen LL, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, and Kerbel RS (2006). Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 66, 3639-3648.
9. Smith NR, James NH, Oakley I, Wainwright A, Copley C, Kendrew J, Womersley LM, Jurgensmeier JM, Wedge SR, and Barry ST (2007). Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 6, 2198-2208.
10. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, et al. (2007). Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharm 59, 561-574.
11. Palmowski M, Huppert J, Hauff P, Reinhardt M, Schreiner K, Socher MA, Hallscheidt P, Kauffmann GW, Semmler W, and Kiessling F (2008). Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. Cancer Res 68, 7042-7049.
12. Bozec A, Gros FX, Penault-Llorca F, Formento P, Cayre A, Dental C, Etienne-Grimaldi MC, Fischel GL, and Milano G (2008). Vertical VEGF targeting: a combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer 44, 1922-1930.
13. Selvakumaran M, Yao KS, Feldman MD, and O'Dwyer PJ (2008). Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharm 75, 627-638.
14. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, and Ferrara N (1998). Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273, 30336-30343.
15. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, et al. (2006). Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116, 2610-2621.
16. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, et al. (2006). Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313, 1785-1787.
17. Shaked Y and Kerbel RS (2007). Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 67, 7055-7058.
18. Burstein HJ, Elias D, Rugo HS, Cobleigh MA,Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, et al. (2008). Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26, 1810-1816.
19. Johannsen M, Florcken A, and Bex A (2009). Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 55, 1430-1439.
20. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, and Kerbel RS (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239.
21. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, and Casanovas DO (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231.
22. Backer MV, Levashova Z, Patel V, Jehning BJ, Claffey K, Blankenberg FG, and Backer JM (2007). Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF based probes. Nat Med 13, 504-509.
23. Levashova Z, Backer M, Backer JM, and Blankenberg FG (2008). Direct labeling of Cys-tag in scVEGF with technetium 99m. Bioconjug Chem 19, 1049-1054.
24. Backer MV, Levashova Z, Levenson R, Blankenberg FG, and Backer JM (2008). Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins. Methods Mol Biol 494, 275-294.
25. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, et al. (2007). Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6, 2012-2021.
26. Sloan B and Scheinfeld NS (2008). Pazopnib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Invest Drugs 9, 1324-1335.
27. Dougher M and Terman BI (1999). Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 18, 1619-1627.
28. Santos SC, Miguel C, Domingues I, Calado A, Zhu Z, Wu Y, and Dias S (2007). VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res 313, 1561-1574.
29. Ewan LC, Jopling HM, Jia H, Mittar S, Bagherzadeh A, Howell GJ, Walker JH, Zachary IC, and Ponnambalam C (2006). Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic 7, 1270-1282.
30. Tang XN, Wang Q, Koike MA, Cheng D, Goris ML, Blankenberg FG, and Yenari MA (2007). Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia. J Nucl Med 48, 1822-1828.
31. Brindle K (2008). New approaches for imaging tumour responses to treatment. Nat Rev Cancer 8, 1-14.
32. Cho HJ, Ackerstaff E, Carlin S, Lupu ME, Wang Y, Rizwan A, O'Donoghue J, Ling CC, Humm JL, Zanzonico PB, et al. (2009). Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic MRI and PET studies of a preclinical tumor model of tumor hypoxia. Neoplasia 11 (3), 247-259.
33. 13C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia 11, 574-582.
34. Casanovas DJ, Hicklin G, Bergers D, and Hanahan D (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309.
35. Ebos JML, Lee CR, and Kerbel RS (2009). Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15, 5020-5025.
36. Loges S, Mazzone M, Hohensinner P, and Carmeliet P (2009). Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15, 167-170.
37. Dempke WC and Heinemann V (2009). Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 45 (7), 1117-1128.
38. Kerbel RS and Kamen BA (2004). The anti-angiogenesis basis of metronomic chemotherapy. Nat Rev Cancer 4, 425-436.
39. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
40. Alavi A and Basu S (2008). Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time? Eur J Nucl Med Mol Imaging 35, 1560-1565.
41. Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, and Wiesmann C (2006). Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 281 (10), 6625-6631.
42. Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, and Zioncheck TF (2002). A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 72 (1), 20-32.
43. Sargent DJ, Rubinstein L, Schwartz L, Dancey JE, Gatsonis C, Dodd LE, and Shankar LK (2009). Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 45, 290-299.